Taysha Gene Therapies, INC Form 4 insider transactions

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, Inc., reported a sale of 200,000 shares under a Rule 10b5-1 trading plan.

John A. Stalfort III, a Director at Taysha Gene Therapies, Inc., acquired restricted stock units and stock options.

Phillip B. Donenberg, a Director at Taysha Gene Therapies, Inc., acquired restricted stock units and stock options on June 1, 2026.

Director Alison S. Long acquired 21,335 shares of common stock and 42,671 stock options in Taysha Gene Therapies, Inc. (TSHA) on June 1, 2026.

Director Laura Sepp-Lorenzino acquired restricted stock units and stock options in Taysha Gene Therapies, Inc. (TSHA) on June 1, 2026.

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, reports transactions involving common stock and employee stock options.

Taysha Gene Therapies' CFO, Kamran Alam, sold 1,655 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Taysha Gene Therapies' President and Head of R&D, Sukumar Nagendran, sold 116,050 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Taysha Gene Therapies CEO Sean P. Nolan sold 178,101 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Taysha Gene Therapies' Chief Financial Officer, Kamran Alam, reported the sale of 102,817 common shares to cover tax liabilities from restricted stock unit vesting.

Taysha Gene Therapies' CFO, Kamran Alam, was granted 359,000 restricted stock units and 231,000 employee stock options.

Taysha Gene Therapies' CEO, Sean P. Nolan, received significant equity awards, including restricted stock units and stock options, effective January 12, 2026.

Taysha Gene Therapies' President and Head of R&D, Sukumar Nagendran, exercised options, sold shares, and received new equity awards.

Taysha Gene Therapies' President and Head of R&D, Sukumar Nagendran, exercised stock options and subsequently sold 370,172 shares of common stock in pre-planned transactions.

Taysha Gene Therapies' President and Head of R&D, Sukumar Nagendran, exercised options and sold a significant portion of his common stock holdings.

Taysha Gene Therapies' Chief Financial Officer, Kamran Alam, sold 54,491 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Taysha Gene Therapies' President and Head of R&D, Sukumar Nagendran, sold 57,054 shares of common stock to cover tax liabilities from restricted stock unit vesting.

John A. Stalfort III, a Director at Taysha Gene Therapies, Inc., received grants of 56,623 restricted stock units and 113,246 stock options on June 2, 2025, as part of his compensation.

Taysha Gene Therapies, Inc. Director Phillip B. Donenberg was granted 56,623 restricted stock units and 113,246 stock options as part of his compensation, aligning his interests with shareholders.

Taysha Gene Therapies, Inc. Director Alison S. Long has been granted 56,623 restricted stock units and options to purchase 113,246 shares of common stock as part of her compensation.

Taysha Gene Therapies, Inc. director Laura Sepp-Lorenzino was granted 56,623 restricted stock units and options to purchase 113,246 shares of common stock on June 2, 2025, as part of her compensation.

Paul B. Manning, a Director and 10% Owner of Taysha Gene Therapies, Inc., has acquired an additional 750,000 shares of common stock for approximately $2.06 million, signaling strong insider confidence.

Kamran Alam, CFO of Taysha Gene Therapies, files an amended Form 4 to report a previously omitted stock option award granted in February 2023 that vested on May 31, 2023.

Chief Financial Officer of Taysha Gene Therapies, Kamran Alam, reports the disposal of shares to cover tax obligations related to vesting restricted stock units.

Taysha Gene Therapies CEO, Sean P. Nolan, received a significant grant of stock options and restricted stock units, according to a recent SEC filing.

Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, was granted stock options and restricted stock units (RSUs) according to a Form 4 filing.

Taysha Gene Therapies' Chief Financial Officer, Kamran Alam, was granted 431,000 restricted stock units and 431,000 stock options on January 2, 2025.

Paul B. Manning, a director of Taysha Gene Therapies, acquired 1,333,333 shares of common stock at $2.25 per share on June 27, 2024.

Director John A. Stalfort III reports acquiring shares and stock options in Taysha Gene Therapies, Inc.

Director Alison S. Long reports acquisition and disposal of Taysha Gene Therapies shares and stock options related to restricted stock units and stock options vesting on May 29, 2025, or the next annual stockholders meeting.